New hope for tough brain cancer: Triple-Drug attack shows promise

NCT ID NCT05698147

Recruiting now Disease control Sponsor: Tong Chen, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a three-drug combination (selinexor, methotrexate, and rituximab) in 30 adults with central nervous system lymphoma that has relapsed or not responded to treatment. The goal is to find the safest dose and see how well the combo works. Participants receive the drugs in cycles, and those who improve may continue maintenance therapy for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selinexor (a drug that blocks a protein helping cancer cells survive), combined with methotrexate and rituximab (standard chemotherapy and targeted therapy)
What this could lead to: If successful, this could offer a new treatment option for people with central nervous system lymphoma that has come back or not responded to prior therapy.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination may cause significant side effects, and the study is not designed to prove a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Beijing Tiantan Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Department of Hematology, Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200040, China
Oncology Department of The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITING

Zhengzhou, Henan, 450052, China
The First Affiliated Hospital Of Anhui Medical University
NOT_YET_RECRUITING

Hefei, Anhui, China
The First Affiliated Hospital Of Fujian Medical University
NOT_YET_RECRUITING

Fuzhou, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.